Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CRIZOTINIB`

ID	`REG-CRIZOTINIB-IMT`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-SARCOMA`

Notes

STUB scaffold. Dosing summary only.

Used By

Indication

IND-IMT-ALK-CRIZOTINIB - IND-IMT-ALK-CRIZOTINIB